Blocking of the Sphenopalatine ganglion (nerve cells located behind the nose) is an effective treatment for acute migraine headaches

Sphenopalatine ganglion block for the treatment of acute migraine headache

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN13783111

Enrollment

Registered

2018-01-08

Start date

2017-03-01

Completion date

Unknown

Last updated

2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute migraine headache Nervous System Diseases Acute migraine headache

Interventions

Prior to procedure, the nose is inspected for any obstruction, and xylometazoline 0.05% nasal drops (one drop in each nostril) are used to help open the nasal passages. Face temperature is recorded us

this was recorded at baseline, 15 minutes, 2 hours and 24 hours after the procedure. We also recorded patient global impression of change (PGIC

very poor, poor, no change, good, very good) at 2 hours and 24 hours post-procedure.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged between 18 to 60 years of age 2. Diagnosed with migraine headache (according to International Classification of Headache Disorders-3 Beta since at least one year) 3. Present with moderate to severe headache not responding to abortive medications

Exclusion criteria

Exclusion criteria: 1. Patients with medication overuse headache 2. Bleeding disorders 3. Abnormal neurological examination 4. History of allergy to local anesthetics

Design outcomes

Primary

Measure	Time frame
1. Percentage of patients free of headache using the numeric rating scale at 15 minutes, 2 hours and 24 hours 2. Pain is assessed using the numeric rating scale (NRS) at baseline, 15 minutes, 2 hours and 24 hours after the procedure	—

Secondary

Measure	Time frame
1. Headache relief rate, defined as percentage of patients with 50% or more reduction in headache intensity is measured using the numeric rating scale (NRS) at 15 minutes, 2 hours and 24 hours (using the NRS) 2. Change in NRS from baseline to 15 minutes, 2 hours and 24 hours post-treatment 3. Patient global impression of change (on a scale: very poor, poor, no change, good, very good), measuring effects on headache and its associated symptoms, and tolerability) at 2 hours and 24 hours 4. All adverse events reported by the patients up to 24 hours post-procedure	—

Measure

Time frame

1. Headache relief rate, defined as percentage of patients with 50% or more reduction in headache intensity is measured using the numeric rating scale (NRS) at 15 minutes, 2 hours and 24 hours (using the NRS) 2. Change in NRS from baseline to 15 minutes, 2 hours and 24 hours post-treatment 3. Patient global impression of change (on a scale: very poor, poor, no change, good, very good), measuring effects on headache and its associated symptoms, and tolerability) at 2 hours and 24 hours 4. All adverse events reported by the patients up to 24 hours post-procedure

—

Countries

Bahrain

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026